Cutaneous ulcers: An unusual manifestation of inherited thrombophilia

American Journal of Hematology

Volumn 76, Issue 2, 2004, Pages 139-142

  Mavragani, Clio P ^a   Pikazis, Dimitris ^a   Aroni, Kyriaki ^a   Paikos, Spiros ^b   Voulgarelis, Michalis ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b LAIKO GENERAL HOSPITAL   (Greece)

Author keywords

Cutaneous ulcers; Factor Leiden; Livedoid vasculitis; Protein S deficiency

Indexed keywords

ACETYLSALICYLIC ACID; ACTIVATED PROTEIN C; BLOOD CLOTTING FACTOR 5 LEIDEN; HEPARIN; WARFARIN;

ADULT; ANTICOAGULATION; ARTICLE; CASE REPORT; CLINICAL EXAMINATION; DEEP VEIN THROMBOSIS; FEMALE; HISTOPATHOLOGY; HUMAN; MALE; PRIORITY JOURNAL; PROTEIN S DEFICIENCY; SKIN BIOPSY; SKIN ULCER; THROMBOPHILIA;

ANTICOAGULANTS; HUMANS; MALE; MIDDLE AGED; SKIN ULCER; THROMBOPHILIA; TREATMENT OUTCOME;

EID: 2542583215     PISSN: 03618609     EISSN: None     Source Type: Journal    
DOI: 10.1002/ajh.20077     Document Type: Article

References (19)

1. Dahlback B. Activated protein C resistance and thrombosis: molecular mechanisms of hypercoagulable state due to FVR506Q mutation. Semin Thromb Hemost 1999;25:273-289.
2. Gaber Y, Siemens HJ, Schmeller W. Resistance to activated protein C due to factor V Leiden mutation: high prevalence in patients with post-thrombotic leg ulcers. Br J Dermatol 2001;144:546-548.
3. Calamia KT, Balabanova M, Perniciaro C, Walsh JS. Livedo (livedoid) vasculitis and the factor V Leiden mutation: additional evidence for abnormal coagulation. J Am Acad Dermatol 2002;46: 133-137.
4. Biedermann T, Flaig MJ, Sander CA. Livedoid vasculopathy in a patient with factor V mutation (Leiden). J Cutan Pathol 2000;27: 410-412.
5. Cocuroccia B, Tonanzi T, Menaguale G, Fazio M, Girolomoni G. Livedoid vasculopathy and skin ulcers in patients with inherited thrombophilia. Eur J Dermatol 2002;12:360-363.
6. Baccard M, Vignon-Pennamen MD, Janier M, Scrobohaci ML, Dubertret L. Livedo vasculitis with protein C system deficiency. Arch Dermatol 1992;128:1410-1411.
7. Goodwin AJ, Rosendaal FR, Kottke-Marchant K, Bovill EG. A review of the technical, diagnostic, and epidemiologic considerations for protein S assays. Arch Pathol Lab Med 2002(Nov);126(11): 1349-1366.
8. Price DT, Ridker PM. Factor V Leiden mutation and the risks for thromboembolic disease: a clinical perspective Ann Intern Med 1997;127:895-903.
9. Ridker, PM, Miletich, JP, Buring, HE, et al. Factor V Leiden mutation as a risk factor for recurrent pregnancy loss. Ann Intern Med 1998;128:1000.
10. Koeleman, BPC, Reitsma, PH, Bertina, RM. Familial thrombophilia: a complex genetic disorder. Semin Hematol 1997;34:256.
11. Moake JL. Thrombotic microangiopathies. N Engl J Med 2002; 347:589-600.
12. Ng T, Tillyer ML. Warfarin-induced skin necrosis associated with Factor V Leiden and protein S deficiency. Clin Lab Haematol. 2001;23:261-264.
13. Furlan M, Robles R, Galbusera M, Remuzzi G, et al. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 1998;339:1578-1584.
14. Glas-Greenwalt P, Hall JM, Panke TW, Kant KS, Allen CM, Pollak VE. Fibrinolysis in health and disease: abnormal levels of plasminogen activator, plasminogen activator inhibitor, and protein C in thrombotic thrombocytopenic purpura. J Lab Clin Med 1986;108:415-422.
15. Raife TJ, Lentz SR, Atkinson BS, Vesely SK, Hessner MJ. Factor V Leiden: a genetic risk factor for thrombotic microangiopathy in patients with normal von Willebrand factor-cleaving protease activity. Blood 2002;99:437-442.
16. Levine JS, Branch DW, Rauch J. The antiphospholipid syndrome. N Engl J Med 2002;346:752-763.
17. Sakaguchi S, Kitazawa K, Watanabe M, et al. A case of primary antiphospholipid antibody syndrome with acute renal failure showing thrombotic microangiopathy. Am J Nephrol 1999;19: 594-598.
18. Gennari LC, Blanco AN, Alberto MF, Grosso SH, Peirano AA, Lazzari MA. Antiphospholipid antibodies impact the protein C (PC) pathway behavior. Am J Hematol 2002;71:128-130.
19. Nojima, J, Kuratsune, H, Suehisa, E, et al. Acquired activated protein C resistance is associated with the co-existence of antiprothrombin antibodies and lupus anticoagulant activity in patients with systemic lupus erythematosus. Br J Haematol 2002;118:577.